Anne-Marie Koop

304 55. Borgdorff MA, Bartelds B, Dickinson MG, Wiechen MPH van, Steendijk P, Vroomen M de, Berger RMF. Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload. Am J Physiol Circ Physiol 2014;307:H361–H369. 56. Velde AR Van Der, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, Veldhuisen DJ Van, Boer RA De. Prognostic value of changes in galectin-3 levels over time in patients with heart failure data from CORONA and COACH. Circ Hear Fail 2013;6:219–226. 57. Boer RA De, Lok DJA, Jaarsma T, Meer PVan Der, Voors AA, Hillege HL, Veldhuisen DJ Van. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60–68. 58. Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol Elsevier Ireland Ltd; 2015;182:168–170. 59. Dumic J, Dabelic S, Flögel M. Galectin-3: An open-ended story. Biochim Biophys Acta - Gen Subj 2006;1760:616–635. 60. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230:160–171. 61. Marín F, Roldán V. Biomarkers: GDF-15 and risk stratification in atrial fibrillation. Nat Rev Cardiol Nature Publishing Group; 2015;12:8–9. 62. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Relation of growth-differentiation factor 15 to left ventricular remodeling in ST-segment elevation myocardial infarction. Am J Cardiol Elsevier Inc.; 2011;108:955–958. 63. Li J, Li Q, Jia W, Liu K, Qi X, Cui Y, Huang A. Additional diagnostic value of growth differentiation factor-15 (GDF-15) to N-Terminal B-Type natriuretic peptide (NT-proBNP) in patients with different stages of heart failure. Med Sci Monit 2018;24:4992–4999. 64. Norozi K, Buchhorn R, Yasin A, Geyer S, Binder L, Seabrook JA, Wessel A. Growth differentiation factor 15: An additional diagnostic tool for the risk stratification of developing heart failure in patients with operated congenital heart defects? Am Heart J Mosby, Inc.; 2011;162:131–135. 65. Eindhoven JA, Bosch AE Van Den, Oemrawsingh RM, Baggen VJ, Kardys I, Cuypers JA, Witsenburg M, Schaik RH Van, Roos-Hesselink JW, Boersma E. Release of growth- differentiation factor 15 and associations with cardiac function in adult patients with congenital heart disease. Int J Cardiol Elsevier Ireland Ltd; 2016;202:246–251. 66. Lyle MA, Iyer SR, Redfield MM, Reddy YNV, Felker GM, Cappola TP, Hernandez AF, Scott CG, Burnett JC, Pereira NL. Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. JACC Hear Fail 2020;8:70–80. 67. Bayés-Genís A, Barallat J, Galán A, Antonio M De, Domingo M, Zamora E, Urrutia A, Lupón J. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardio l 2015;65:657–665.